Carcinoembryonic Antigen (CEA) is a tumour-associated antigen characterized as an oncofetal glycoprotein. CEA is expressed in a variety of malignancies, particularly pulmonary or gastrointestinal tumours (e. G. Colon cancer, liver cancer and lung cancer). CEA normally occurs in fetal gut tissue with detectable serum levels essentially disappearing after birth. Therefore, elevated levels of CEA can be of significant value in the diagnosis of primary carcinomas.
In addition to qualitative assessment, CEA -testing plays an important role in the monitoring of cancer patients. Clinical evidence indicates that CEA levels can serve as predictive markers in both pre- and post-treatment cancer. Progressive elevation of CEA may signal tumour recurrence 3-36 months before clinical evidence of metastasis. Persistent elevation of circulating CEA following treatment is strongly indicative of occult metastasis and residual diseases and deficient therapeutic response.
Blue Cross One Step CEA Test is a rapid chromatographic immunoassay for the qualitative detection of CEA in human blood specimens. It is used as an aid in the clinical management of colorectal, breast, lung and pancreatic cancers. The minimum detection level is 5ng/ml.